J3393 — Injection, betibeglogene autotemcel, per treatment
J3393 is a HCPCS Level II code for injection, betibeglogene autotemcel, per treatment. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusE
Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
The CMS record for J3393
- Long descriptor
- Injection, betibeglogene autotemcel, per treatment
- Short descriptor
- Inj, betibeglogene autotemce
- Added
- July 1, 2024
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J3393
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J3393 is not quite right, the correct code is very often within a few positions of it.
- J3379Injection, valproate sodium, 5 mg
- J3380Injection, vedolizumab, intravenous, 1 mg
- J3385Injection, velaglucerase alfa, 100 units
- J3386Injection, etuvetidigene autotemcel, per treatment
- J3387Injection, elivaldogene autotemcel, per treatment
- J3389Topical administration, prademagene zamikeracel, per treatment
- J3391Injection, atidarsagene autotemcel, per treatment
- J3392Injection, exagamglogene autotemcel, per treatment
- J3394Injection, lovotibeglogene autotemcel, per treatment
- J3396Injection, verteporfin, 0.1 mg
- J3397Injection, vestronidase alfa-vjbk, 1 mg
- J3398Injection, voretigene neparvovec-rzyl, 1 billion vector genomes
- J3399Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes
- J3400Injection, triflupromazine hcl, up to 20 mgterminated
- J3401Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml
- J3402Injection, remestemcel-l-rknd, per therapeutic dose
Questions about J3393
What is HCPCS code J3393?
J3393 is a HCPCS Level II code for injection, betibeglogene autotemcel, per treatment. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J3393?
The CMS HCPCS file marks J3393 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
How is J3393 paid under the physician fee schedule?
J3393 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).